Magungunan ƙwayoyin cuta na CAR T ya zama sabuwar hanya don magance nau'ikan ciwon daji da yawa, kuma Isra'ila ta sami ci gaba sosai a wannan fannin. Cibiyoyin kiwon lafiya na Isra'ila sun kasance a kan ƙarshen binciken CAR T cell far da haɓakawa, suna ba marasa lafiya da ke fama da cutar kansar jini waɗanda ba su amsa wasu fata na jiyya ba. Masana kimiyya na Isra'ila sun taimaka ƙirƙira da yin ƙwayoyin CAR T, wanda ya inganta tasiri da amincin su. An yi amfani da maganin tantanin halitta na CAR T cikin nasara akan marasa lafiya a asibitocin Isra'ila kamar Sheba Medical Center, asibitin Tel Aviv, da Cibiyar Kiwon Lafiya ta Hadassah. Wannan ya haifar da gafara mai ban mamaki da yawan mace-mace. Har yanzu Isra'ila na da matukar muhimmanci ga ci gaban maganin CAR T, wanda ke ba masu cutar kansa a duk duniya sabon bege.
CAR T cell far, wani sabon nau'in immunotherapy wanda ke yin babban fantsama a fagen kula da ciwon daji, misali ne mai kyau. Shahararrun asibitoci da cibiyoyin nazari a Isra'ila sun kasance kan gaba wajen haɓakawa da yin amfani da wannan sabon magani, suna ba da bege ga mutanen da ke da nau'in ciwon daji daban-daban. CAR T-Cell far a cikin Isra'ila yanzu ana samunsa a asibitoci da yawa.
The Sheba Medical Center yana ɗaya daga cikin wurare mafi kyau a Isra'ila don samun maganin CAR T. Ya kafa Cibiyar Kula da Hannu immunotherapy, wanda ke da alhakin yin da bayar da keɓaɓɓen mutum CAR T cell far. Tawagar ƙwararrun Sheba sun sami ci gaba mai ban mamaki wajen taimaka wa mutane da su cutar kansa kamar cutar sankarar bargo da lymphoma. Marasa lafiya daga ko'ina cikin duniya masu son ci gaban jiyya suna zuwa wurinsu saboda iliminsu da kayan aikin zamani.
Wani muhimmin wuri shi ne Cibiyar Kiwon Lafiya ta Hadassah da ke Urushalima, wadda ta yi nazari da yawa game da maganin ƙwayoyin cuta na CAR T. Babban burin su shine don taimakawa yara masu fama da cutar sankarar bargo (ALL) wanda ya dawo ko bai amsa magani ba. Labarun nasara daga Hadassah sun ba da bege ga iyalai da ke cikin mawuyacin hali, saboda CAR T cell far na iya zama hanyar rayuwa ga waɗanda ke da ƴan zaɓin magani.
A cikin 'yan shekarun nan, maganin ƙwayar cuta ta CAR T ya sami ci gaba mai yawa a Isra'ila. Masu bincike sun kasance suna neman hanyoyin da za su sa magungunan suyi aiki mafi kyau da kuma taimakawa mutane da yawa. Ɗaya daga cikin waɗannan shine amfani da ƙwayoyin CAR T tare da manufa guda biyu daban-daban. Ta hanyar bin antigens da yawa a lokaci ɗaya, wannan hanyar tana da nufin sanya maganin ya sami nasara kuma ya rage haɗarin tserewa antigen, wanda shine lokacin da ƙwayoyin cutar kansa ke guje wa sel CAR T su gane su.
Har ila yau, masana kimiyya na Isra'ila sun yi ta duban sabbin hanyoyin da za a bi don magance ciwon daji, wanda ya fi wuyar magani fiye da cututtukan jini a baya. Masu bincike a Cibiyar Kiwon Lafiya ta Tel Aviv Sourasky sun yi gwajin kwayoyin halittar CAR T da aka canza don sanya su samar da karin kwayoyin da za su iya inganta su wajen kashe ciwace-ciwace. Sakamakon farko yana da kyau, wanda ke ba wa mutane fatan cewa CAR T cell far zai iya zama babban ci gaba wajen magance ciwace-ciwacen daji.
CAR T cell far ya canza yadda ake bi da ciwon daji, yana ba marasa lafiya sabbin zaɓuɓɓuka da sabon bege. A cikin Isra'ila, mafi kyawun asibitoci da cibiyoyin karatu suna ci gaba da tura iyakokin wannan jiyya, suna ƙoƙarin sanya shi aiki mafi kyau da kuma taimaka wa ƙarin mutane. Yayin da bincike ke ci gaba, mai yiwuwa maganin CAR T zai zama mafi mahimmanci a Isra'ila da ma duniya baki daya a yaki da ciwon daji.
Kudin jiyya na CAR T-Cell a Isra'ila ya yi ƙasa sosai fiye da na ƙasashe kamar Amurka, UK, Australia, Japan, Koriya da Singapore. CAR T-Cell far a Isra'ila na iya tsada kawai $ 75-100,000 USD. Isra'ila tana da kwatankwacin babban wadatar magungunan CAR T. Isra'ila ta kafa cibiyoyi da asibitoci masu kula da nau'ikan ciwon daji daban-daban tare da maganin CAR-T. Wadannan cibiyoyi sun dade suna yin irin wannan magani kuma suna da damar samun kayayyakin more rayuwa da kayan aikin da suke bukata. Lokacin zabar inda za'a sami magungunan CAR-T, yana da mahimmanci a yi tunani game da samuwa.
Lokacin da aka kera samfuran T-cell na CAR a cikin gida, suna da ƙimar nasara iri ɗaya da CAR ta kasuwanci ta hanyar pharma, ba tare da kusan kuskuren masana'anta ba. Sarrafa dukkan tsari akan wurin yana nufin cewa za'a iya yanke lokacin daga leukapheresis zuwa gwamnatin CAR zuwa kusan kwanaki 10. Wannan yana nufin cewa mara lafiya ba dole ba ne ya bi ta hanyar haɗin gwiwa, wanda ke da alaƙa da kyakkyawan sakamako. A takaice dai lokacin jiyya gabaɗaya ya ragu zuwa kwanaki 30 kawai idan aka kwatanta da kwanaki 60-75 a wasu ƙasashe.
An san Isra'ila don kyakkyawan karatun likitanta da sabbin dabaru. Ƙasar ta sami ci gaba mai mahimmanci ga immunotherapy, ciki har da CAR-T cell far. Likitoci da ma'aikatan jinya na Isra'ila galibi su ne na farko don haɓakawa da amfani da sabbin jiyya, suna tabbatar da cewa majiyyatan su sun sami mafi kyawun kulawa.
Aika rahoton likitan ku zuwa info@cancerfax.com ko kuma WhatsApp su +1-213 789-56-55 ko Kira +91 96 1588 1588. Aika rahotanni masu zuwa don ra'ayi da kimantawa:
1) Takaitawar likitanci
2) Sabbin rahotannin jini
3) Biopsy
4) Sabbin Binciken PET
5) Biopsy marrow biopsy (Idan akwai)
6) Duk wani rahoton da ya dace da dubawa
Da zarar ƙungiyarmu ta karɓi rahoton ku na likitanci, muna bincika su kuma mu aika zuwa asibitocin da ke yin maganin CAR T-Cell tare da irin wannan nau'in ciwon daji da alamar. Muna aika rahotanni zuwa ga kwararrun da abin ya shafa kuma mu sami ra'ayinsa. Muna kuma samun kiyasi daga asibiti kan cikakken magani. Wannan yana taimaka muku wajen tsara duk tsawon lokacin jiyya.
Da zarar ka yanke shawarar ziyartar magani, mun shirya wasiƙar takardar visa ta likita da sauran takaddun da suka dace daga asibiti. Muna kuma taimaka muku da kuma jagorance ku wajen neman takardar izinin likita zuwa ofishin jakadancin Isra'ila. Da zarar an shirya biza za mu taimaka da shiryar da ku don shirya tikitin tafiya da jirgin sama. Muna kuma shirya otal ɗin ku da gidan baƙi, idan an buƙata a Isra'ila. Bayan isa birnin jiyya wakilin mu zai maraba da ku a filin jirgin sama.
Wakilinmu zai shirya wa likita alƙawarin kuma ya cika muku ƙa'idodin rajista da suka dace. Zai kuma taimaka muku da shigar ku asibiti da sauran taimako da tallafi na gida waɗanda ake buƙata. Bayan an gama jinyar za mu shirya tuntubar ku tare da likitan jinya.
CAR T-cell far, wanda ake yi a Asibitin Sheba da ke Tel Aviv, Isra’ila, wani babban ci gaba ne na magance cutar kansa. Yana ba mutanen da ke da wasu nau'ikan ciwon daji na jini bege. A cikin Ibrananci, ana kiran Asibitin Sheba Tel HaShomer. Shi ne babban asibiti a Isra'ila kuma jagora a fannin CAR T-cell far.
Asibitin Sheba yana da kayan aikin yankan-baki da fasaha don taimakawa tare da CAR T-cell far. Asibitin yana da raka'a na musamman waɗanda aka kafa tare da sabbin fasahohi don kera ƙwayoyin cuta. Wannan yana tabbatar da cewa sel T da aka gyaggyarawa CAR kowane majiyyaci an yi su cikin sauri da aminci. Har ila yau, ƙungiyar likitoci da ma'aikatan jinya a asibitin Sheba suna da kwarewa mai yawa wajen gudanar da gwaje-gwaje na asibiti da kuma nazarin maganin CAR T-cell, wanda ke taimaka wa wannan filin ya ci gaba da ingantawa.
Cibiyar Kiwon Lafiya ta Tel Aviv Sourasky (Asibitin Ichilov) wuri ne da za ku iya samun sabon nau'in magani da ake kira motar T-cell therapy. A cikin wannan sabon magani, ƙwayoyin T na majiyyacin suna canzawa ta kwayoyin halitta ta yadda za su iya ganewa kuma su kai hari kan ƙwayoyin cutar kansa. Jikin mai haƙuri yana cike da waɗannan ƙwayoyin da aka canza a cikin lab. A can, za su iya samun kuma su kashe kwayoyin cutar kansa. Shirin T-cell na Mota a Cibiyar Kiwon Lafiya ta Tel Aviv Sourasky yana gudanar da ƙungiyar likitoci da ƙwararrun ƙwararrun ƙwayoyin cuta waɗanda ke da ƙwarewa mai yawa. Marasa lafiya da ke da nau'ikan ciwon daji daban-daban na iya samun bege tare da wannan zaɓi na ci gaba na jiyya, wanda ke ba su hanyar keɓantacce kuma mai inganci don yaƙar cutar.
The Hadassah Medical Centre in Jerusalem is at the heart of a new way to treat cancer called Car T-cell therapy. Car T-cell therapy changes and activates T cells so they can recognise and fight cancer cells. It does this by using the power of the patient’s own immune system. The skilled group of doctors and experts at Hadassah work together to provide this cutting-edge therapy. Hadassah Medical Centre gives people with different kinds of cancer hope and better outcomes with its cutting-edge equipment and dedication to new ideas. Car T-cell therapy at Hadassah is a shining example of progress in the field of oncology. It gives patients choices for personalized and targeted treatment.
Ɗauki ra'ayi na biyu na ƙwararru akan jiko na CAR T-Cell daga mafi kyawun CAR T-Cell ƙwararrun jiyya a Isra'ila.
CAR T-Cell far
Profile: Arnon Nagler, ya yi aiki na shekaru da yawa a matsayin darekta na Sashen Ilimin Jiki da Ciwon Jini na Kashi da Bankin Jini na Cord a Cibiyar Kiwon Lafiya ta Chaim Sheba, kuma Farfesa na Magunguna a Jami'ar Tel Aviv, Isra'ila.
Ilimin Jiyya na Yara
Profile: Farfesa Amos Toren shi ne Daraktan Cibiyar Hemato-Oncology na Yara da BMT, wanda aka tabbatar da shi a fannin ilimin yara, Janar Hematology da Pediatric Hemato-Oncology. Ya yi aiki a matsayin Shugaban sashin ilimin Hematology a Makarantar Magunguna ta Sackler Jami'ar Tel-Aviv na sharuɗɗan 2.
CAR T-Cell far
Profile: Farfesa Dina Ben-Yehuda, shugabar Sashen Nazarin Jiki na Hadassah Medical Organization, an nada shi shugabar tsangayar ilimin likitanci na Jami’ar Hadassah-Hebrew – mace ta farko da ta samu wannan matsayi.
Farashin CAR T-Cell far a Isra'ila yana farawa daga $ 75,000 USD ya danganta da alamar CAR T da aka zaɓa. Kudin maganin CAR T na gida na gida zai kusan $ 80,000 yayin da na hanyoyin kwantar da hankali kamar Kymeriah da Breyanzi farashin na iya haura $ 470,000. Kudin maganin T-cell na mota zai iya bambanta a Isra'ila bisa abubuwa da yawa, kamar cibiyar kiwon lafiya, nau'in ciwon daji da ake yi, da lafiyar majiyyaci. Maganin T-cell na mota magani ne mai rikitarwa kuma na musamman wanda ya haɗa da canza kwayoyin halitta da baiwa kowane majiyyaci kulawar kansa. Saboda wannan, hanya ce mai tsada. Gabaɗaya, farashin maganin T-cell na Mota ya haɗa da tsarin aikin injiniyan kwayoyin halitta, asibiti, kudade na ma'aikatan kiwon lafiya, da bin diddigin bayan jiyya. Ya kamata marasa lafiya suyi magana da ma'aikatan kiwon lafiya da kamfanonin inshora don gano ko menene farashin zai iya zama da irin taimakon kuɗi ko fa'idodin inshora.
Chimeric antigen receptor T-cell far, wanda aka fi sani da CAR T-cell therapy, wani maganin rigakafi ne mai rushe ƙasa wanda ya canza gaba ɗaya yadda ake bi da ciwon daji. Yana ba wa marasa lafiya da wasu cututtukan daji fata waɗanda aka gani a baya a matsayin ba za a iya warkewa ba ko kuma suna da ƴan hanyoyin warkewa.
Maganin ya haɗa da yin amfani da ƙwayoyin rigakafi na majiyyaci-musamman, ƙwayoyin T-da kuma gyara su don inganta ƙarfin su don ganowa da lalata ƙwayoyin cutar kansa. Don yin wannan, ana ba da ƙwayoyin T na ƙwayoyin cuta na chimeric antigen receptor (CAR), wanda ke ba su ikon kai hari kan wasu sunadaran sunadaran, ko antigens, a saman ƙwayoyin cutar kansa.
An fara cire ƙwayoyin T daga majiyyaci, sannan a canza su ta hanyar kwayoyin halitta don bayyana CAR. A cikin dakin gwaje-gwaje, waɗannan sel da aka canza suna haɓaka don samar da adadi mai yawa na ƙwayoyin CAR T, sannan a mayar da su cikin jinin mara lafiya.
Da zarar sun shiga cikin jiki, ƙwayoyin CAR T suna samun ƙwayoyin kansa waɗanda ke bayyana antigen da ake so, suna manne musu, kuma suna haifar da amsawar rigakafi. Kwayoyin CAR T da aka kunna suna yaduwa kuma suna kai hari kan ƙwayoyin cutar kansa, suna kashe su.
Lokacin da aka yi amfani da shi don magance wasu cututtuka na jini kamar m lymphoblastic cutar sankarar bargo (ALL) da takamaiman nau'i na lymphoma, CAR T-cell far ya nuna sakamako na musamman. Ya haifar da ƙima mai ƙima da kuma a wasu marasa lafiya, har ma da dawwamammen gafara.
CAR T-cell far, duk da haka, hanya ce mai ƙwarewa kuma ta musamman wacce za ta iya samun haɗari da illa. Cytokine saki ciwo (CRS), wani tartsatsi na rigakafi dauki wanda zai iya haifar da mura-kamar bayyanar cututtuka da kuma, a cikin matsananci yanayi, gabobin jiki gazawar, na iya dandana daga wasu mutane. Haka kuma an sami rahotanni game da illar cutar jijiya, duk da haka ana iya warkewa akai-akai.
Duk da waɗannan matsalolin, CAR T-cell far wani gagarumin ci gaba ne a cikin yaƙi da ciwon daji kuma yana nuna babban damar nan gaba. Binciken na yanzu yana mai da hankali kan haɓaka ingancinsa da bayanin martabarsa tare da faɗaɗa amfaninsa zuwa nau'ikan ciwon daji daban-daban. CAR T-cell far yana da ikon canza fuskar maganin ciwon daji da ba marasa lafiya a ko'ina sabon bege tare da ci gaba.
Ana fitar da ƙwayoyin T daga jinin ku ta amfani da bututu da aka sanya cikin jijiya ta hannu. Wannan yana ɗaukar sa'o'i biyu.
Kwayoyin T ana jigilar su zuwa wani wuri inda suke yin gyare-gyaren kwayoyin halitta don zama ƙwayoyin CAR-T. Makonni biyu zuwa uku sun wuce duk wannan.
Ana sake dawo da ƙwayoyin CAR-T cikin jinin ku ta ɗigo. Wannan yana buƙatar sa'o'i da yawa.
Kwayoyin CAR-T sun yi niyya kuma suna kawar da kwayoyin cutar kansa a cikin jiki. Bayan karbar maganin CAR-T, za a sa ido sosai.
Sai kawai marasa lafiya da balagaggu B-cell wanda ba lymphoma Hodgkin ko yara masu fama da cutar sankarar lymphoblastic na yara waɗanda suka riga sun gwada jiyya na al'ada guda biyu waɗanda ba su yi nasara ba a halin yanzu suna iya amfani da samfuran CAR T-cell waɗanda suka sami amincewar FDA. Koyaya, yanzu ana gwada maganin CAR T-cell a cikin karatun asibiti azaman jiyya na layi na farko ko na biyu don ƙwayar lymphoma balagaggu da cutar sankarar yara mai tsanani na lymphoblastic na yara. Kwanan nan, wasu daga cikin binciken sun nuna nasarori masu ban mamaki a lokuta masu ƙarfi kamar glioblastoma, gliomas, ciwon hanta, ciwon huhu, ciwon GI, ciwon daji na pancreatic da kuma ciwon daji na baki.
Wannan yana wakiltar ci gaba mai mahimmanci a cikin kula da cutar sankarar bargo da B-cell lymphoma. Bugu da ƙari, yana ba da bege ga waɗanda aka yi hasashen rayuwarsu za ta wuce watanni shida kacal. Yanzu da muka gano hanyoyin juriya kuma mun ƙirƙiri ƙarin dabaru don yaƙar su, nan gaba yana da alama ya fi dacewa.
Tuntuɓi ƙwararrun ƙwararrun masu ba da lafiya a nan a Faxar Cancer don shawarwari na kyauta don tsara tsarin kulawa mai dacewa don bukatun ku na kiwon lafiya. Da fatan za a aika da rahoton likitan ku zuwa info@cancerfax.com ko WhatsApp zuwa + 1 213 789 56 55.
Babban fa'idar ita ce maganin CAR T-cell yana buƙatar jiko ɗaya kawai kuma galibi yana buƙatar makonni biyu na kulawar marasa lafiya. Marasa lafiya da lymphoma ba Hodgkin da cutar sankarar yara da aka gano kwanan nan, a gefe guda, yawanci suna buƙatar chemotherapy na akalla watanni shida ko fiye.
Amfanin maganin CAR T-cell, wanda shine ainihin magani mai rai, na iya dawwama shekaru da yawa. Idan kuma lokacin da sake dawowa ya faru, ƙwayoyin za su iya ganowa da kuma kai hari ga ƙwayoyin cutar kansa saboda suna iya rayuwa a cikin jiki na tsawon lokaci.
Kodayake bayanin yana ci gaba, kashi 42 cikin 19 na marasa lafiya na lymphoma manya waɗanda suka yi amfani da CD15 CAR T-cell magani har yanzu suna cikin gafara bayan watanni XNUMX. Kuma bayan watanni shida, kashi biyu bisa uku na marasa lafiya da ke fama da cutar sankarar mahaifa mai tsanani na lymphoblastic na yara har yanzu suna cikin gafara. Abin takaici, waɗannan majiyyatan suna da ciwace-ciwacen ciwace-ciwacen daji waɗanda ba a samu nasarar yi musu magani ta amfani da ƙa'idodin kulawa na gargajiya ba.
An gwada marasa lafiya tsakanin shekaru 3 zuwa shekaru 70 tare da maganin CAR T-Cell don nau'in ciwon daji na jini daban-daban kuma an gano yana da tasiri sosai. Cibiyoyi da yawa sun yi iƙirarin ƙimar nasara fiye da 80%. Mafi kyawun ɗan takarar don CAR T-cell far a wannan lokacin shine ƙaramin yaro tare da cutar sankarar lymphoblastic mai tsanani ko kuma balagagge tare da lymphoma mai tsanani na B-cell wanda ya riga ya sami layi biyu na rashin tasiri.
Kafin ƙarshen 2017, babu wani tsarin kulawa da aka yarda da shi ga marasa lafiya waɗanda suka riga sun shiga cikin layi biyu na jiyya ba tare da samun gafara ba. Magani kawai da FDA ta amince da shi wanda ya zuwa yanzu ya tabbatar da cewa yana da fa'ida sosai ga waɗannan marasa lafiya shine CAR T-cell far.
CAR T-cell far ya kasance mai tasiri sosai wajen magance wasu nau'in ciwon daji na jini, kamar cutar sankarar bargo na lymphoblastic (ALL) da lymphoma ba Hodgkin. A cikin gwaje-gwaje na asibiti, ƙimar amsawar sun kasance da kyau sosai, kuma yawancin marasa lafiya sun shiga cikin cikakkiyar gafara. A wasu lokuta, mutanen da suka gwada kowane magani sun sami gafara na dindindin ko ma yiwuwar warkewa.
Ɗaya daga cikin mafi kyawun abubuwa game da maganin CAR T-cell shine cewa yana kai hari ga ƙwayoyin da suka dace. Masu karɓar CAR waɗanda aka ƙara zuwa ƙwayoyin T suna iya samun takamaiman alamomi akan ƙwayoyin cutar kansa. Wannan yana ba da damar ba da magani da aka yi niyya. Wannan hanyar da aka yi niyya tana cutar da ƙwayoyin lafiya kaɗan gwargwadon yuwuwa kuma tana rage haɗarin illolin da ke zuwa tare da jiyya na gargajiya kamar chemotherapy.
Amma yana da mahimmanci a tuna cewa CAR T-cell far har yanzu wani sabon yanki ne wanda har yanzu yana canzawa. Masu bincike da likitoci suna aiki tuƙuru don magance matsaloli kamar tsadar tsada, yuwuwar sakamako mai tsanani, da gaskiyar cewa yana aiki ne kawai ga wasu nau'ikan cutar kansa.
A ƙarshe, maganin CAR T-cell ya nuna hanya ce mai nasara sosai don magance wasu nau'in ciwon daji na jini. Ko da yake hanya ce mai ban sha'awa da ƙarfi, ana buƙatar ƙarin nazari da gwaje-gwaje na asibiti don inganta shi da nemo sababbin hanyoyin amfani da shi. CAR T-cell far na iya canza yadda ake bi da kansa kuma ya sa abubuwa su zama mafi kyau ga mutane a duk faɗin duniya idan ta ci gaba da samun gyaruwa.
1. Marasa lafiya tare da CD19 + B-cell Lymphoma (Akalla haɗuwa 2 kafin lokaci chemotherapy tsarin mulki)
2. Yayi shekaru 3 zuwa 75
3. ECOG ci ≤2
4. Matan da ke da damar haihuwa dole ne a yi gwajin ciki na fitsari kuma an tabbatar da rashin kyau kafin magani. Duk marasa lafiya sun yarda su yi amfani da ingantattun hanyoyin hana haihuwa a lokacin gwajin har zuwa bin diddigin na ƙarshe.
1. Hawan jini a cikin kwakwalwa ko suma
2. Rashin numfashi
3. Yada yaduwar jijiyoyin cikin jini
4. Hematosepsis ko Ciwo mai aiki mara ƙarfi
5. Ciwon suga mara tsari.
B-cell precursor m lymphoblastic cutar sankarar bargo, koma baya ko refractory yaduwa babban B-cell lymphoma
Cikakken ƙimar amsawa (CR):> 90%
Saukewa: CD19
Farashin: $ 475,000
Lokacin amincewa: Agusta 30, 2017
Mai sake dawowa ko refractory yana yaduwa babban lymphoma na B-cell, relapsed ko refractory follicular cell lymphoma
Cikakkun martanin Cikakkun Amsa na Ciwon lymphoma ba Hodgkin (CR): 51%
Saukewa: CD19
Farashin: $ 373,000
Lokacin amincewa: Oktoba 2017, 18
Maimaitawa ko mai jujjuyawa yana yaduwa babban lymphoma na B-cell
Cikakkar amsa ƙimar lymphoma na Mantle cell (CR): 67%
Saukewa: CD19
Farashin: $ 373,000
Lokacin da aka amince: Oktoba 18, 2017
Maimaitawa ko mai jujjuyawa yana yaduwa babban lymphoma na B-cell
Cikakken ƙimar amsawa (CR): 54%
Saukewa: CD19
Farashin: $ 410,300
Lokacin da aka amince: Oktoba 18, 2017
Maimaitawa ko Mai Rarraba Multiple Myeloma
Cikakken ƙimar amsawa: 28%
Saukewa: CD19
Farashin: $ 419,500
An amince da shi: Oktoba 18, 2017
A ƙasa an ambata wasu daga cikin illolin maganin CAR T-Cell.
Yana da kyau a tuna cewa ba kowane majiyyaci ne zai sami waɗannan illolin ba, kuma matakin hankalin kowane mutum zai bambanta. Don ragewa da rage girman waɗannan abubuwan da zasu iya haifar da illa, ƙungiyar likitocin suna bincikar marasa lafiya sosai kafin, lokacin, da kuma bayan maganin CAR T-cell.
Bincika ƙasa jimlar firam ɗin lokacin da ake buƙata don kammala aikin CAR T-Cell. Kodayake tsarin lokaci ya dogara da yawa akan nisan lab daga asibitin da ya shirya na CAR.
Jimlar lokacin: 10-12 Makonni
Ciwon Saki na Cytokine (CRS) wani tsarin rigakafi ne wanda sau da yawa ke haifar da wasu jiyya kamar immunotherapy ko CAR-T cell far. Ya ƙunshi yawan sakin cytokines, yana haifar da alamun bayyanar da ke fitowa daga zazzabi da gajiya zuwa rikice-rikice masu haɗari masu haɗari kamar lalacewar gabbai. Gudanarwa yana buƙatar kulawa da hankali da dabarun shiga tsakani.
Ma'aikatan jinya suna taka muhimmiyar rawa a cikin nasarar CAR T-cell far ta hanyar tabbatar da kulawar marasa lafiya a duk lokacin aikin jiyya. Suna ba da tallafi mai mahimmanci yayin sufuri, lura da mahimman alamun marasa lafiya, da gudanar da ayyukan gaggawa na likita idan rikitarwa ta taso. Amsar su da sauri da kulawar ƙwararrun suna ba da gudummawa ga amincin gabaɗaya da ingancin jiyya, sauƙaƙe sauye-sauye masu sauƙi tsakanin saitunan kiwon lafiya da haɓaka sakamakon haƙuri a cikin ƙalubalen shimfidar wurare na ci-gaba na salon salula.
A fagen ilimin ciwon daji, bayyanar maganin da aka yi niyya ya canza yanayin yanayin jiyya don ci gaba da cutar kansa. Ba kamar chemotherapy na al'ada ba, wanda ke yin niyya ga sel masu rarraba cikin sauri, maganin da aka yi niyya yana nufin kai hari a kan ƙwayoyin cutar kansa yayin da yake rage lalacewa ga sel na yau da kullun. Wannan madaidaicin tsarin yana yiwuwa ta hanyar gano takamaiman sauye-sauyen ƙwayoyin cuta ko alamomin halittu waɗanda ke keɓanta da ƙwayoyin cutar kansa. Ta hanyar fahimtar bayanan kwayoyin halitta na ciwace-ciwacen daji, masu ilimin likitancin jiki na iya tsara tsarin jiyya wanda ya fi tasiri da rashin guba. A cikin wannan labarin, mun zurfafa cikin ƙa'idodi, aikace-aikace, da ci gaban jiyya da aka yi niyya a cikin ci gaban kansa.
Gabatarwa Immunotherapy ya zama hanya mai ban sha'awa a cikin maganin ciwon daji, musamman don maganin ciwon daji na mataki-mataki wanda ya nuna ƙarancin tasiri tare da daidaitattun magunguna. Wannan
Shiga cikin rikitattun rayuwa da kulawa na dogon lokaci ga mutanen da ke fuskantar cututtukan daji masu tasowa. Gano sabbin ci gaba a cikin daidaitawar kulawa da tafiya ta tunani na tsira daga cutar kansa. Kasance tare da mu yayin da muke bincika makomar kulawa ta tallafi ga waɗanda suka tsira daga cutar kansa.
Gabatarwa Ko da a cikin marasa lafiya da suka cancanta (TE), jiyya na layin farko don babban haɗari (HR) sabbin cututtukan myeloma da yawa (NDMM) suna da sakamako mara kyau. Babban inganci, amintaccen magani na CAR-T zai iya